Amneal Pharmaceuticals, Inc. (AMRX) along with Shilpa Medicare Limited, Thursday announced that the U.S. Food and Drug Administration has approved BORUZU, the first ready-to-use version of bortezomib for subcutaneous administration.
The companies expect to launch the bortezomib injection in the second quarter of 2025, which could be used for the treatment of multiple myeloma and mantle cell lymphoma.
"These ready-to-use injectable presentations are important innovations for oncology providers as they reduce the pharmacy preparation steps for clinicians," said Sean McGowan, Vice President, Biosimilars and Branded Oncology.
For comments and feedback contact: editorial@rttnews.com
Health News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.